Hailshadow/iStock via Getty Images
Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene therapy, Elevidys, designed for Duchenne muscular dystrophy (DMD), Bloomberg News reported Sunday.
The death follows a similar incident three months ago, in which